Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
Abstract Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials f...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2023-10-01
|
| Series: | Journal of Biomedical Science |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12929-023-00976-6 |
| _version_ | 1797451930869432320 |
|---|---|
| author | Li-Kai Huang Yi-Chun Kuan Ho-Wei Lin Chaur-Jong Hu |
| author_facet | Li-Kai Huang Yi-Chun Kuan Ho-Wei Lin Chaur-Jong Hu |
| author_sort | Li-Kai Huang |
| collection | DOAJ |
| description | Abstract Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD. |
| first_indexed | 2024-03-09T15:01:34Z |
| format | Article |
| id | doaj.art-f9b90e7313dd47d099a43581187cdb16 |
| institution | Directory Open Access Journal |
| issn | 1423-0127 |
| language | English |
| last_indexed | 2024-03-09T15:01:34Z |
| publishDate | 2023-10-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Biomedical Science |
| spelling | doaj.art-f9b90e7313dd47d099a43581187cdb162023-11-26T13:55:14ZengBMCJournal of Biomedical Science1423-01272023-10-0130111910.1186/s12929-023-00976-6Clinical trials of new drugs for Alzheimer disease: a 2020–2023 updateLi-Kai Huang0Yi-Chun Kuan1Ho-Wei Lin2Chaur-Jong Hu3PhD Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical UniversityTaipei Neuroscience Institute, Taipei Medical UniversitySchool of Medicine, College of Medicine, Taipei Medical UniversityPhD Program in Medical Neuroscience, College of Medical Science and Technology, Taipei Medical UniversityAbstract Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet medical need worldwide. The pathogenesis of AD involves various pathophysiological events, including the accumulation of amyloid and tau, neuro-inflammation, and neuronal injury. Clinical trials focusing on new drugs for AD were documented in 2020, but subsequent developments have emerged since then. Notably, the US-FDA has approved Aducanumab and Lecanemab, both antibodies targeting amyloid, marking the end of a nearly two-decade period without new AD drugs. In this comprehensive report, we review all trials listed in clinicaltrials.gov, elucidating their underlying mechanisms and study designs. Ongoing clinical trials are investigating numerous promising new drugs for AD. The main trends in these trials involve pathophysiology-based, disease-modifying therapies and the recruitment of participants in earlier stages of the disease. These trends underscore the significance of conducting fundamental research on pathophysiology, prevention, and intervention prior to the occurrence of brain damage caused by AD.https://doi.org/10.1186/s12929-023-00976-6Alzheimer diseaseClinical trialsAnti-amyloidAnti-tauNeuroprotectionCognitive enhancement |
| spellingShingle | Li-Kai Huang Yi-Chun Kuan Ho-Wei Lin Chaur-Jong Hu Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update Journal of Biomedical Science Alzheimer disease Clinical trials Anti-amyloid Anti-tau Neuroprotection Cognitive enhancement |
| title | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update |
| title_full | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update |
| title_fullStr | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update |
| title_full_unstemmed | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update |
| title_short | Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update |
| title_sort | clinical trials of new drugs for alzheimer disease a 2020 2023 update |
| topic | Alzheimer disease Clinical trials Anti-amyloid Anti-tau Neuroprotection Cognitive enhancement |
| url | https://doi.org/10.1186/s12929-023-00976-6 |
| work_keys_str_mv | AT likaihuang clinicaltrialsofnewdrugsforalzheimerdiseasea20202023update AT yichunkuan clinicaltrialsofnewdrugsforalzheimerdiseasea20202023update AT howeilin clinicaltrialsofnewdrugsforalzheimerdiseasea20202023update AT chaurjonghu clinicaltrialsofnewdrugsforalzheimerdiseasea20202023update |